Acute lymphoblastic leukaemia: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CD19 122
• CD22 33
• ABL1 10
• KMT2A 8
• CD20 8
• TP53 0
• AKT 0
• BCL-2 3
• PI3K 0
• CD123 5
• JAK 2
• CD38 4
• PD-1 3
• RUNX1 0
• mTOR 0
• NPM1 4
• BCMA 4
• NOTCH1 0
• CXCR4 1
• PTEN 0
• CTNNB1 0
• EGFR 0
• HDAC 0
• IDH 0
• MYC 0
• RAS 0
• STAT3 0
• AMPK 0
• CD30 0
• CD40 0
• CD47 0
• ERK 0
• FGFR 0
• MAPK 0
• MDM2 0
• PD-L1 0
• CD33 1
• FLT3 0
• IL-1 0
• IL-17 0
• IL-6 0
• KRAS 0
• MEK 0
• PPAR 0
• RANKL 0
• RB1 0
• TYK2 0
• ALK 0
• AXL 0
• BRCA1 0
• BRD4 0
• BTK 0
• CDK4/6 0
• CDKN2A 0
• CTLA-4 0
• EZH2 0
• FAK 0
• FTO 0
• GPRC5D 1
• GPX4 0

24 of 41+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  Overcoming CD4 T Cell Dysfunction in Acute Lymphoblastic Leukemia

  University of Minnesota· Minneapolis, United States· US$38,277 awarded in fiscal year 2026· until Sept 2029

• NIH NCI · R41

  Bivalent CD47 Immunotoxin for Targeted Therapy of T-Cell Acute Lymphoblastic Leukemia

  Rock Immune, Inc.· Denver, United States· US$400,000 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R34

  Adapting a caregiver-directed mHealth intervention to support positive health behaviors in children treated for Acute Lymphoblastic Leukemia

  University of Minnesota· Minneapolis, United States· US$298,864 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · R01

  Targeting inflammatory RAS-mutated AML leukemia stem cells

  Icahn School of Medicine at Mount Sinai· New York, United States· US$573,098 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R43

  Validating the reduced immunogenicity of novel human-like asparaginases to de-risk clinical development

  Enzyme By Design, Inc.· Chicago, United States· US$400,000 awarded in fiscal year 2026· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  TOWARDS THE ELIMINATION OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN THROUGH IDENTIFICATION OF THEIR ENVIRONMENTAL CAUSES (ELI-ALL)

  Centre International de Recherche Sur Le Cancer· Lyon 7eme, France· EU contribution €6,502,240· until Aug 2031· 12 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX (THANATOS)

  Commissariat A L Energie Atomique Et Aux Energies Alternatives· Paris, France· EU contribution €13,557,641· until Aug 2031· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Role of RAS mutant subclones in the development of High Hyperdiploid B-ALL (RasWayToALL)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €200,400· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Science, Innovation, Health, Earth, And Life Technologies for ALL (SCIENCE4ALL)

  Istinye University· Istanbul, Türkiye· EU contribution €350,000· until Jun 2028

10 of 294 running projects, newest first. Listed amounts together: US$164.5m + €62.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL

  NCT06985498· The First Affiliated Hospital of Soochow University· Updated 29 May 2026

  “According to the new regulations of China, newly launched clinical trials involved CAR-T cells must be apporved first by China National Center for Biotechology Development.”Registry text, quoted unchanged. Source

• Terminated

  Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

  NCT03913559· St. Jude Children's Research Hospital· Updated 12 Feb 2026

  “Closed due to slow accrual”Registry text, quoted unchanged. Source

• Terminated

  ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

  NCT03698552· M.D. Anderson Cancer Center· Updated 12 Dec 2025

  “\<75% participation”Registry text, quoted unchanged. Source

• Terminated

  A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

  NCT05292898· Institute of Hematology & Blood Diseases Hospital, China· Updated 3 Jun 2025

  “Achieve the proof of concept”Registry text, quoted unchanged. Source

• Withdrawn

  CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia

  NCT05168748· Novartis Pharmaceuticals· Updated 21 Dec 2022

  “Sponsor's decision”Registry text, quoted unchanged. Source

• Withdrawn

  Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

  NCT03851081· Roswell Park Cancer Institute· Updated 28 Jan 2022

  “no accrual”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

  NCT07109219· AstraZeneca· Source

• Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

  NCT03226704· National Cancer Institute (NCI)· Source

• CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  NCT05442515· National Cancer Institute (NCI)· Source

• CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

  NCT07328503· National Cancer Institute (NCI)· Source

• CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL

  NCT05470777· The First Affiliated Hospital of Soochow University· Source

• Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

  NCT02315612· National Cancer Institute (NCI)· Source

• Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

  NCT03913559· St. Jude Children's Research Hospital· Source

• A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

  NCT05687032· Pfizer· Source

• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

  NCT03448393· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 5
• Gene Expression Profiling 27
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 4
• Flow Cytometry 40
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 50
• Magnetic Resonance Imaging 14
• Machine Learning 11
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 8

• Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells.

  Nat Commun, Oct 2026

• Template-independent poly-adenine elongation enables multivalent CRISPR/Cas12a activation for amplified lateral flow biosensing.

  Talanta, May 2026

• [Novel CD6-targeted CAR-T cell therapy for T-cell acute lymphoblastic leukemia: a safe and efficient strategy to prevent fratricide through gene editing].

  Zhonghua Xue Ye Xue Za Zhi, May 2026

• A genome-wide CRISPR/Cas9 screen reveals novel positive regulators of FTY720 sensitivity in acute lymphoblastic leukemia cells.

  BMC Res Notes, Jan 2026

• CRISPR in Medicine: A Systematic Review of Clinical Trials and Therapeutic Applications.

  Hum Gene Ther, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.